Illicit Opioid Use and Treatment for Opioid Dependence: Challenges for Canada and beyond

Giffen J Endicott S Lambert S. Panic and indifference—the politics of Canada's drug laws. Ottawa (ON): Canadian Centre on Substance Abuse; 1991.

Le Dain Commission. Commission of Inquiry into the Non-Medical Use of Drugs—treatment report. Ottawa (ON): Information Canada; 1972.

Courtwright D. Dark paradise: Opiate addiction in America before 1940. Cambridge (MA): Harvard University Press; 1982.

Fischer B Kirst M Rehm J Marsh D Bondy S Tyndall M. The phenomenon of so-called ‘other drug use’ among opiate addicts in the North American context: Evidence, consequences, questions. In: Westermann B Bellman G Jellinek C , editors. Beigebrauch Offene Grenzen der Substitution.Weinheim (DE): BELTZ Deutscher Studien Verlag; 2000. p 95–118.

Fischer B Cruz M Firestone Rehm J. Illicit opioid use and its key characteristics: A select overview and evidence from a Canadian multi-site cohort of illicit opioid users (OPICAN). Can J Psychiatry 2006;51:624–34.

Wild C el-Guebaly N Fischer B Brissette S Brochu S , and others. Comorbid depression among opiate users: Results from a multisite Canadian study. Can J Psychiatry 2005;50:512–8.

Sulkowski M Thomas D. Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clinical Infectious Diseases 2005;40(suppl 5):S263–S269.

Fischer B Brissette S Brochu S Bruneau J el-Guebaly N Noël L , and others. Prevalence and determinants of overdose incidents among illicit opioid users in five cities across Canada. CMAJ 2004;171:235–9.

Rehm J Baliunas D Brochu S Fischer B Gnam W Patra J , and others. The costs of substance abuse in Canada 2002. Ottawa (ON): Canadian Centre on Substance Abuse (CCSA); 2006.

Health Officers Council of British Columbia. A public health approach to drug control in Canada. Victoria (BC); 2005.

Hankins C. Substance use: Time for drug law reform. CMAJ 2000;162:1693–4.

Compton W Volkow N. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83(Suppl 1);S4–S7.

van den Brink W Haasen C. Evidence based treatment of opioid dependent patients. Can J Psychiatry 2006;51:635–46.

Mattick R Digiusto E Doran C O'Brien S Shanahan M Kimber J , and others. National evaluation of pharmacotherapies for opioid dependence (NEPOD): Report of results and recommendations. [No. 52]. Sydney (AU): National Drug and Alcohol Research Centre; 2001.

Johnson R Chutuape M Strain E Walsh S Stitzer M Bigelow G. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 2000;343:1290–7.

Rehm J Gschwend P Steffen T Gutzwiller F Dobler-Mikola A Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001;358:1417–20.

Fischer B. Prescriptions, power and politics: The turbulent history of methadone maintenance in Canada. J Pub Health Pol 2000;21:187–210.

Paulus I Halliday R. Rehabilitation and the narcotic addict: Results of a comparative methadone withdrawal program. CMAJ 1967;96:655–9.

Schechter MT . NAOMI—her time has come. North American Opiate Medication Initiative. J Urban Health 2002;79:164–5.

Schottenfeld R Chawarski M Pakes J Pantalon M Carroll K Kosten T. Methadone versus buprenorphine with contingency management or performance feedback for cocaine opioid dependence. Am J Psychiatry 2005;162:340–9.

Best D Harris J Gossop M Farrell M Finch E Noble A , and others. Use of non-prescribed methadone and other illicit drugs during methadone maintenance treatment. Drug and Alcohol Review 2000;19:9–16.

Khantzian E. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harv Rev Psychiatry 1997;4:231–44.

Minkoff K. Developing standards of care for individuals with co-occurring psychiatric and substance use disorders. Psychiatr Serv 2001;52:597–9.

Remis R. A study to characterize the epidemiology of hepatitis C infection in Canada. Final report. Ottawa (ON): Health Canada; 2004.

Edlin BR Kresina TF Raymond DB Carden MR Gourevitch MN Rich JD , and others. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases 2005;40(suppl 5):S276–S285.

Sylvestre DL Litwin A Clements B Gourevitch M. The impact of barriers to hepatitis C treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005;29:159–65.